Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Amortizatization of Intangibles: 2016-2025

Historic Amortizatization of Intangibles for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $704,000.

  • Ultragenyx Pharmaceutical's Amortizatization of Intangibles fell 77.40% to $704,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 54.31%. This contributed to the annual value of $12.6 million for FY2024, which is 1.70% down from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Amortizatization of Intangibles stood at $704,000, which was down 32.76% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Amortizatization of Intangibles ranged from a high of $3.9 million in Q4 2023 and a low of -$2.1 million during Q4 2021.
  • Its 3-year average for Amortizatization of Intangibles is $2.6 million, with a median of $2.9 million in 2024.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Amortizatization of Intangibles plummeted by 947.33% in 2021, and later spiked by 376.68% in 2023.
  • Ultragenyx Pharmaceutical's Amortizatization of Intangibles (Quarterly) stood at -$2.1 million in 2021, then skyrocketed by 178.31% to $1.6 million in 2022, then surged by 139.27% to $3.9 million in 2023, then fell by 28.93% to $2.8 million in 2024, then slumped by 77.40% to $704,000 in 2025.
  • Its last three reported values are $704,000 in Q3 2025, $1.0 million for Q2 2025, and $1.7 million during Q1 2025.